Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses

References

• Valero-Rello A, Sanjuán R. Enveloped viruses show increased propensity to cross-species transmission and zoonosis. Proc Natl Acad Sci. 2022;119(50):e2215600119. doi: 10.1073/pnas.2215600119
   PubMed Web of Science ®Google Scholar
• Xiang Q; Li L; Wu J; Tian M; Fu Y. Application of pseudovirus system in the development of vaccine, Antiviral-Drugs, and neutralizing antibodies. Microbiol Res. 2022;258:126993. doi: 10.1016/j.micres.2022.126993
   PubMed Web of Science ®Google Scholar
• Kalkeri R, Cai Z, Lin S, et al. SARS-CoV-2 Spike Pseudoviruses: a useful tool to study virus entry and address emerging neutralization escape phenotypes. Microorganisms. 2021;9(8):1744. doi: 10.3390/microorganisms9081744
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang X-E. Construction and applications of SARS-CoV-2 pseudoviruses: a mini review. Int J Biol Sci. 2021;17(6):1574–1580. doi: 10.7150/ijbs.59184
   PubMed Web of Science ®Google Scholar
• Cheresiz SV, Kononova AA, Razumova Y, et al. A Vesicular Stomatitis Pseudovirus Expressing the Surface Glycoproteins of Influenza A Virus. Arch Virol. 2014;159(10):2651–2658. doi: 10.1007/s00705-014-2127-y
   PubMed Web of Science ®Google Scholar
• Wool-Lewis RJ, Bates P. Characterization of ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol. 1998;72(4):3155–3160. doi: 10.1128/JVI.72.4.3155-3160.1998
   PubMed Web of Science ®Google Scholar
• Najafi Fard S, Petrone L, Petruccioli E, et al. In vitro models for studying entry, tissue tropism, and therapeutic approaches of highly pathogenic coronaviruses. Biomed Res Int. 2021;2021:e8856018. doi: 10.1155/2021/8856018
   PubMed Web of Science ®Google Scholar
• Cosset F-L, Marianneau P, Verney G, et al. Characterization of lassa virus cell entry and neutralization with lassa virus pseudoparticles. J Virol. 2009;83(7):3228–3237. doi: 10.1128/JVI.01711-08
   PubMed Web of Science ®Google Scholar
• Kunz S, Rojek JM, Perez M, et al. Characterization of the interaction of lassa fever virus with its cellular receptor α-dystroglycan. J Virol. 2005;79(10):5979–5987. doi: 10.1128/JVI.79.10.5979-5987.2005
   PubMed Web of Science ®Google Scholar
• Robinson JE, Hastie KM, Cross RW, et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both lassa virus glycoprotein subunits. Nat Commun. 2016;7(1):11544. doi: https://doi.org/10.1038/ncomms11544
   PubMedGoogle Scholar
• Klewitz C, Klenk H-D, Ter Meulen J. Amino acids from both N-Terminal hydrophobic regions of the lassa virus envelope glycoprotein GP-2 are critical for pH-Dependent membrane fusion and infectivity. J Gen Virol. 2007;88(Pt 8):2320–2328. doi: 10.1099/vir.0.82950-0
   PubMedGoogle Scholar
• Radoshitzky SR; Abraham J; Spiropoulou CF; Kuhn JH; Nguyen D; Li W; Nagel J; Schmidt PJ; Nunberg JH; Andrews NC; Farzan M; Choe H. Transferrin Receptor 1 Is a Cellular Receptor for New World Haemorrhagic Fever Arenaviruses. Nature. 2007;446(7131):92–96. doi: 10.1038/nature05539
   PubMed Web of Science ®Google Scholar
• Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albariño CG. Lassa and ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Res. 2016;136:9–18. doi: 10.1016/j.antiviral.2016.10.007
   PubMed Web of Science ®Google Scholar
• Steffen I, Simmons G. Pseudotyping viral vectors with emerging Virus envelope proteins. Curr Gene Ther. 2016;16(1):47–55. doi: 10.2174/1566523216666160119093948
   PubMed Web of Science ®Google Scholar
• Grehan K, Ferrara F, Temperton N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX. 2015;2:379–384. doi: 10.1016/j.mex.2015.09.003
   PubMedGoogle Scholar
• Wang Q, Qi J, Yuan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe. 2014;16(3):328–337. doi: 10.1016/j.chom.2014.08.009
   PubMed Web of Science ®Google Scholar
• Zhao G, Du L, Ma C, et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013;10:266. doi: 10.1186/1743-422X-10-266
   PubMed Web of Science ®Google Scholar
• Yang Y, Du L, Liu C, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A. 2014;111(34):12516–12521. doi: 10.1073/pnas.1405889111
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, Yang Y, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in middle east respiratory syndrome coronavirus spike protein. J Virol. 2014;88(12):7045–7053. doi: 10.1128/JVI.00433-14
   PubMed Web of Science ®Google Scholar
• Fujioka Y, Kashiwagi S, Yoshida A, et al. A method for the generation of pseudovirus particles bearing SARS coronavirus spike protein in high yields. Cell Struct Funct. 2022;47(1):43–53. doi: 10.1247/csf.21047
   PubMed Web of Science ®Google Scholar
• He Y, Zhu Q, Liu S, et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology. 2005;334(1):74–82. doi: 10.1016/j.virol.2005.01.034
   PubMed Web of Science ®Google Scholar
• Nie Y, Wang P, Shi X, et al. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem Biophys Res Commun. 2004;321(4):994–1000. doi: 10.1016/j.bbrc.2004.07.060
   PubMed Web of Science ®Google Scholar
• Dadonaite B, Crawford KHD, Radford CE, et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 Spike. Cell. 2023;186(6):1263–1278.e20. doi: 10.1016/j.cell.2023.02.001
   PubMed Web of Science ®Google Scholar
• Donofrio G; Franceschi V; Macchi F; Russo L; Rocci A; Marchica V; Costa F; Giuliani N; Ferrari C; Missale G. A Simplified SARS-CoV-2 pseudovirus neutralization assay. Vaccines. 2021;9(4):389. doi: 10.3390/vaccines9040389
   Web of Science ®Google Scholar
• Yang P; Yang Y; Wu Y; Huang C; Ding Y; Wang X; Wang S. An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research. J Virol Methods. 2021;295:114221. doi: 10.1016/j.jviromet.2021.114221
   PubMed Web of Science ®Google Scholar
• Fu X; Tao L; Zhang X. Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. Mol Ther - Methods Clin Dev. 2021;20:350–356. doi: 10.1016/j.omtm.2020.12.007
   PubMed Web of Science ®Google Scholar
• Kobinger GP; Weiner DJ; Yu QC; Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol. 2001;19(3):225–230. doi: 10.1038/85664
   PubMed Web of Science ®Google Scholar
• Takada A, Robison C, Goto H, et al. A system for functional analysis of ebola virus glycoprotein. Proc Natl Acad Sci U S A. 1997;94(26):14764–14769. doi: 10.1073/pnas.94.26.14764
   PubMed Web of Science ®Google Scholar
• Urbanowicz RA, McClure CP, King B, et al. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. J Gen Virol. 2016;97(9):2265–2279. doi: 10.1099/jgv.0.000537
   PubMedGoogle Scholar
• Bi J; Wang H; Pei H; Han Q; Feng N; Wang Q; Wang X; Wang Z; Wei S; Ge L; Wu M; Liang H; Yang S; Yan F; Zhao Y; Xia X. A novel and secure pseudovirus reporter system based assay for neutralizing and enhancing antibody assay against marburg virus. Front Microbiol. 2022;13. doi: 10.3389/fmicb.2022.927122
   Web of Science ®Google Scholar
• Chan SY, Speck RF, Ma MC, et al. Distinct mechanisms of entry by envelope glycoproteins of marburg and ebola (Zaire) viruses. J Virol. 2000;74(10):4933–4937. doi: 10.1128/jvi.74.10.4933-4937.2000
   PubMed Web of Science ®Google Scholar
• Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. J Infect Dis. 2004;189(8):1440–1443. doi: 10.1086/382658
   PubMed Web of Science ®Google Scholar
• Cruz-Oliveira C, Freire JM, Conceição TM, et al. Receptors and routes of dengue virus entry into the Host cells. FEMS Microbiol Rev. 2015;39(2):155–170. doi: 10.1093/femsre/fuu004
   PubMed Web of Science ®Google Scholar
• Tani H; Shiokawa M; Kaname Y; Kambara H; Mori Y; Abe T; Moriishi K; Matsuura Y. Involvement of ceramide in the propagation of Japanese encephalitis virus. J Virol. 2010;84(6):2798–2807. doi: 10.1128/JVI.02499-09
   PubMed Web of Science ®Google Scholar
• Negrete OA; Levroney EL; Aguilar HC; Bertolotti-Ciarlet A; Nazarian R; Tajyar S; Lee B. EphrinB2 is the entry receptor for nipah virus, an emergent deadly paramyxovirus. Nature. 2005;436(7049):401–405. doi: 10.1038/nature03838
   PubMed Web of Science ®Google Scholar
• Pierson TC, Sánchez MD, Puffer BA, et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of west Nile virus infection. Virology. 2006;346(1):53–65. doi: 10.1016/j.virol.2005.10.030
   PubMed Web of Science ®Google Scholar
• Mercier-Delarue S, Durier C, Colin de Verdière N, et al. Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype. PLoS One. 2017;12(5):e0177882. doi: 10.1371/journal.pone.0177882
   PubMed Web of Science ®Google Scholar
• Kretschmer M, Kadlubowska P, Hoffmann D, et al. Zikavirus prME envelope pseudotyped human immunodeficiency virus type-1 as a novel tool for Glioblastoma-Directed Virotherapy. Cancers (Basel). 2020;12(4):1000. doi: 10.3390/cancers12041000
   PubMed Web of Science ®Google Scholar
• Rana J, Slon Campos JL, Leccese G, et al. Role of Capsid Anchor in the morphogenesis of Zika Virus. J Virol. 2018;92(22): doi: 10.1128/jvi.01174-18
   PubMed Web of Science ®Google Scholar
• Higa MM, Petersen J, Hooper J, et al. Efficient Production of hantaan and puumala pseudovirions for viral tropism and neutralization studies. Virology. 2012;423(2):134–142. doi: 10.1016/j.virol.2011.08.012
   PubMed Web of Science ®Google Scholar
• Lee B-H; Yoshimatsu K; Araki K; Okumura M; Nakamura I; Arikawa J. A pseudotype vesicular stomatitis virus containing hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice. Vaccine. 2006;24(15):2928–2934. doi: 10.1016/j.vaccine.2005.12.040
   PubMed Web of Science ®Google Scholar
• Renoux VMG, Fleury MJJ, Bousarghin L, et al. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice. Vaccine. 2008;26(51):6602–6607. doi: 10.1016/j.vaccine.2008.09.035
   PubMed Web of Science ®Google Scholar
• Di Genova C; Sutton G; Paillot R; Temperton N; Pronost S; Scott SD. Studying longitudinal neutralising antibody levels against equid herpesvirus 1 in experimentally infected horses using a novel pseudotype based assay. Virus Res. 2024;339:199262. doi: 10.1016/j.virusres.2023.199262
   PubMedGoogle Scholar
• Suda Y; Fukushi S; Tani H; Murakami S; Saijo M; Horimoto T; Shimojima M. Analysis of the entry mechanism of crimean-congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system. Arch Virol. 2016;161(6):1447–1454. doi: 10.1007/s00705-016-2803-1
   PubMed Web of Science ®Google Scholar
• Zimmer G, Locher S, Berger Rentsch M, et al. Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses. J Gen Virol. 2014;95(Pt 8):1634–1639. doi: 10.1099/vir.0.065201-0
   PubMedGoogle Scholar
• Tian Y; Zhao H; Liu Q; Zhang C; Nie J; Huang W; Li C; Li X; Wang Y. Development of in vitro and in vivo neutralization assays based on the pseudotyped H7N9 virus. Sci Rep. 2018;8(1):8484. doi: 10.1038/s41598-018-26822-6
   PubMedGoogle Scholar
• Wang W; Butler EN; Veguilla V; Vassell R; Thomas JT; Moos M; Ye Z; Hancock K; Weiss CD. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods. 2008;153(2):111–119. doi: 10.1016/j.jviromet.2008.07.015
   PubMed Web of Science ®Google Scholar
• Nie J, Liu L, Wang Q, et al. Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities. Emerg Microbes Infect. 2019;8(1):272–281. doi: 10.1080/22221751.2019.1571871
   PubMed Web of Science ®Google Scholar
• Kaku Y; Noguchi A; Marsh GA; Barr JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang L-F. Second generation of pseudotype-based serum neutralization assay for nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase. J Virol Methods. 2012;179(1):226–232. doi: 10.1016/j.jviromet.2011.11.003
   PubMed Web of Science ®Google Scholar
• Tamin A; Harcourt BH; Lo MK; Roth JA; Wolf MC; Lee B; Weingartl H; Audonnet J-C; Bellini WJ; Rota PA. Development of a neutralization assay for nipah virus using pseudotype particles. J Virol Methods. 2009;160(1–2):1–6. doi: 10.1016/j.jviromet.2009.02.025
   PubMed Web of Science ®Google Scholar
• Kaku Y; Noguchi A; Marsh GA; McEachern JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang L-F. A neutralization test for specific detection of nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. J Virol Methods. 2009;160(1–2):7–13. doi: 10.1016/j.jviromet.2009.04.037
   PubMed Web of Science ®Google Scholar
• Ma M, Kersten DB, Kamrud KI, et al. Murine leukemia virus pseudotypes of La Crosse and Hantaan Bunyaviruses: a system for analysis of cell tropism. Virus Res. 1999;64(1):23–32. doi: 10.1016/s0168-1702(99)00070-2
   PubMed Web of Science ®Google Scholar
• Ma J, Chen R, Huang W, et al. In vitro and in vivo efficacy of a rift valley fever Virus vaccine based on pseudovirus. Hum Vaccines Immunother. 2019;15(10):2286–2294. doi: 10.1080/21645515.2019.1627820
   PubMed Web of Science ®Google Scholar
• Haid S, Grethe C, Bankwitz D, et al. Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral pseudotype system. J Virol. 2016;90(6):3065–3073. doi: 10.1128/JVI.03074-15
   Web of Science ®Google Scholar
• Chen Q, Nie J, Huang W, et al. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. Hum Vaccines Immunother. 2017;14(1):199–208. doi: 10.1080/21645515.2017.1373922
   PubMed Web of Science ®Google Scholar
• Louder MK, Sambor A, Chertova E, et al. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology. 2005;339(2):226–238. doi: 10.1016/j.virol.2005.06.003
   PubMed Web of Science ®Google Scholar
• Chan E, Heilek-Snyder G, Cammack N, et al. Development of a moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors. J Biomol Screen. 2006;11(6):652–663. doi: 10.1177/1087057106288881
   PubMedGoogle Scholar
• Wang W, Nie J, Prochnow C, et al. A systematic study of the N-Glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology. 2013;10(1):14. doi: https://doi.org/10.1186/1742-4690-10-14
   PubMedGoogle Scholar
• Himes JE, Ho C, Nguyen QN, et al. Characterization of simian immunodeficiency virus variants anatomically compartmentalized in plasma and milk in chronically infected African green monkeys. J Virol. 2016;90(19):8795–8808. doi: 10.1128/JVI.00701-16
   PubMed Web of Science ®Google Scholar
• Nie J, Wu X, Ma J, et al. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep. 2017;7(1):42769. doi: 10.1038/srep42769
   PubMedGoogle Scholar
• Salvador B, Zhou Y, Michault A, et al. Characterization of Chikungunya pseudotyped viruses: identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology. 2009;393(1):33–41. doi: 10.1016/j.virol.2009.07.013
   PubMed Web of Science ®Google Scholar
• Hu D, Zhang J, Wang H, et al. Chikungunya Virus Glycoproteins Pseudotype with Lentiviral Vectors and Reveal a Broad Spectrum of Cellular Tropism. PLoS One. 2014;9(10):e110893. doi: 10.1371/journal.pone.0110893
   PubMed Web of Science ®Google Scholar
• Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S. Development of a pseudotyped-lentiviral-vector-based neutralization assay for Chikungunya virus infection. J Clin Microbiol. 2013;51(5):1389–1395. doi: 10.1128/JCM.03109-12
   PubMed Web of Science ®Google Scholar
• Tong W, Yin X-X, Lee B-J, et al. Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein. Acta Virol. 2015;59(2):189–193. doi: 10.4149/av_2015_02_189
   PubMed Web of Science ®Google Scholar
• Sharkey CM; North CL; Kuhn RJ; Sanders DA. Ross river virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J Virol. 2001;75(6):2653–2659. doi: 10.1128/JVI.75.6.2653-2659.2001
   PubMed Web of Science ®Google Scholar
• Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines. 2011;10(10):1415–1433. doi: 10.1586/erv.11.120
   PubMed Web of Science ®Google Scholar
• Zhao J; Nie J; Jiao Y; Li L; Zhang T; Liu Q; Huang W; Wu H; Wang Y. Effect of the maturation of neutralizing antibodies on human immunodeficiency virus (HIV) envelope evolution in HIV-Infected subjects. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2016;38:82–89. doi: 10.1016/j.meegid.2015.12.012
   PubMed Web of Science ®Google Scholar
• Steeds K, Hall Y, Slack GS, et al. Pseudotyping of VSV with ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Sci Rep. 2020;10(1):14289. doi: https://doi.org/10.1038/s41598-020-71225-1
   PubMed Web of Science ®Google Scholar
• Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):1–24. doi: 10.1038/s41392-021-00487-6
   PubMed Web of Science ®Google Scholar
• Moore MJ; Dorfman T; Li W; Wong SK; Li Y; Kuhn JH; Coderre J; Vasilieva N; Han Z; Greenough TC; Farzan M; Choe H. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol. 2004;78(19):10628–10635. doi: 10.1128/JVI.78.19.10628-10635.2004
   PubMed Web of Science ®Google Scholar
• Sandrin V, Boson B, Salmon P, et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood. 2002;100(3):823–832. doi: 10.1182/blood-2001-11-0042
   PubMed Web of Science ®Google Scholar
• Li Q, Liu Q, Huang W, et al. Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018;28:1. doi: 10.1002/rmv.1963
   Web of Science ®Google Scholar
• Labbé RP, Vessillier S, Rafiq QA. Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives. Viruses. 2021;13(8):8. doi: https://doi.org/10.3390/v13081528
   Web of Science ®Google Scholar
• Pollet J; Strych U; Chen W-H; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022;40(26):3655–3663. doi: 10.1016/j.vaccine.2022.05.007
   PubMed Web of Science ®Google Scholar
• Wu X; Fang N; Liang Z; Nie J; Lang S; Fan C; Liang C; Huang W; Wang Y. Development of a Bioluminescent Imaging Mouse Model for SARS-CoV-2 Infection Based on a Pseudovirus System. Vaccines. 2023;11(7):1133. doi: 10.3390/vaccines11071133
   Web of Science ®Google Scholar
• Zhou Y, Agudelo J, Lu K, et al. Inhibitors of SARS-CoV entry – identification using an internally-controlled dual envelope pseudovirion assay. Antiviral Res. 2011;92(2):187–194. doi: 10.1016/j.antiviral.2011.07.016
   PubMed Web of Science ®Google Scholar
• Cruz-Cardenas JA, Gutierrez M, López-Arredondo A, et al. A pseudovirus-based platform to measure neutralizing antibodies in Mexico using sarS-CoV-2 as Proof-of-Concept. Sci Rep. 2022;12(1):17966. doi: 10.1038/s41598-022-22921-7
   PubMed Web of Science ®Google Scholar
• Liu S, Selvaraj P, Lien CZ, et al. The PRRA insert at the S1/S2 site modulates cellular tropism of SARS-CoV-2 and ACE2 usage by the closely related bat RaTG13. J Virol. 2021;95(11):e01751–20. doi: 10.1128/JVI.01751-20
   PubMed Web of Science ®Google Scholar
• Neerukonda SN, Vassell R, Herrup R, et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS One. 2021;16(3):e0248348. doi: 10.1371/journal.pone.0248348
   PubMed Web of Science ®Google Scholar
• Valencia-Reséndiz DG, Palomino-Vizcaino G, Tapia-Vieyra JV, et al. Inhibition of human papillomavirus type 16 infection using an RNA aptamer. Nucleic Acid Ther. 2018;28(2):97–105. doi: 10.1089/nat.2017.0687
   PubMed Web of Science ®Google Scholar
• Nie J; Liu Y; Huang W; Wang Y. Development of a triple-color pseudovirion-based assay to detect neutralizing antibodies against human papillomavirus. Viruses. 2016;8(4):107. doi: 10.3390/v8040107
   PubMed Web of Science ®Google Scholar
• Ma Y; Mao G; Wu G; Chen M; Qin F; Zheng L; Zhang X-E. Dual-fluorescence labeling pseudovirus for real-time imaging of single SARS-CoV-2 entry in respiratory epithelial cells. ACS Appl Mater Interfaces. 2021;13(21):24477–24486. doi: 10.1021/acsami.1c03897
   PubMed Web of Science ®Google Scholar
• Burkard C, Bloyet L-M, Wicht O, et al. Dissecting virus entry: replication-independent analysis of virus binding, internalization, and penetration using minimal complementation of β-galactosidase. PLoS One. 2014;9(7):e101762. doi: 10.1371/journal.pone.0101762
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Buck CB, Pang Y-YS, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004;321(2):205–216. doi: 10.1016/j.virol.2003.12.027
   PubMed Web of Science ®Google Scholar
• Bae DH; Marino M; Iaffaldano B; Fenstermaker S; Afione S; Argaw T; McCright J; Kwilas A; Chiorini JA; Timmons AE; Reiser J. Design and testing of vector-producing HEK293T cells bearing a genomic deletion of the SV40 T antigen coding region. Mol Ther Methods Clin Dev. 2020;18:631–638. doi: 10.1016/j.omtm.2020.07.006
   PubMed Web of Science ®Google Scholar
• Li M; Huang J; Zhu Y; Huang Z; Zhang G; Huang J. Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/Proteasomal pathway. Virol J. 2022;19(1):90. doi: 10.1186/s12985-022-01826-x
   PubMed Web of Science ®Google Scholar
• Liu ML; Winther BL; Kay MA. Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J Virol. 1996;70(4):2497–2502. doi: 10.1128/jvi.70.4.2497-2502.1996
   PubMed Web of Science ®Google Scholar
• Zhang J, Cai Y, Lavine CL, et al. Structural and functional impact by SARS-CoV-2 Omicron Spike Mutations. Cell Rep. 2022;39(4):110729. doi: 10.1016/j.celrep.2022.110729
   PubMed Web of Science ®Google Scholar
• Xiong H-L, Wu Y-T, Cao J-L, et al. Robust neutralization assay based on SARS-CoV-2 S-Protein-Bearing Vesicular Stomatitis Virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect. 2020;9(1):2105–2113. doi: 10.1080/22221751.2020.1815589
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812. doi: 10.1016/j.cell.2020.06.043
   PubMed Web of Science ®Google Scholar
• Kalemera MD, Capella-Pujol J, Chumbe A, et al. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. J Gen Virol. 2020;102(1):jgv001512. doi: 10.1099/jgv.0.001512
   Web of Science ®Google Scholar
• Nie J; Li Q; Wu J; Zhao C; Hao H; Liu H; Zhang L; Nie L; Qin H; Wang M; Lu Q; Li X; Sun Q; Liu J; Fan C; Huang W; Xu M; Wang Y. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15(11):3699–3715. doi: 10.1038/s41596-020-0394-5
   PubMed Web of Science ®Google Scholar
• Hierholzer JC, Killington RA. Virus Isolation and Quantitation. Virol Methods Man. 1996:25–46. doi: 10.1016/B978-012465330-6/50003-8
   Google Scholar
• Savoie C, Lippé R. Optimizing human coronavirus OC43 growth and titration. PeerJ. 2022;10:e13721. doi: 10.7717/peerj.13721
   PubMed Web of Science ®Google Scholar
• Dallner M; Harlow J; Nasheri N. Human coronaviruses do not transfer efficiently between surfaces in the absence of organic materials. Viruses. 2021;13(7):1352. doi: 10.3390/v13071352
   PubMed Web of Science ®Google Scholar
• Kramberger P, Ciringer M, Štrancar A, et al. Evaluation of nanoparticle tracking analysis for total virus particle determination. Virol J. 2012;9(1):265. doi: https://doi.org/10.1186/1743-422X-9-265
   PubMedGoogle Scholar
• Gast M; Sobek H; Mizaikoff B. Nanoparticle tracking of adenovirus by light scattering and fluorescence detection. Hum Gene Ther Methods. 2019;30(6):235–244. doi: 10.1089/hgtb.2019.172
   PubMed Web of Science ®Google Scholar
• Wu C; Xu Q; Wang H; Tu B; Zeng J; Zhao P; Shi M; Qiu H; Huang Y. Neutralization of SARS-CoV-2 Pseudovirus Using ACE2-Engineered Extracellular Vesicles. Acta Pharm Sin B. 2022;12(3):1523–1533. doi: 10.1016/j.apsb.2021.09.004
   PubMed Web of Science ®Google Scholar
• Di Genova C, Sampson A, Scott S, et al. Production, titration, neutralisation, storage and lyophilisation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lentiviral pseudotypes. Bio-Protoc. 2021;11(21):e4236. doi: 10.21769/BioProtoc.4236
   PubMed Web of Science ®Google Scholar
• Zhang Y, Torre JCDL, Melikyan GB, et al. Human LAMP1 accelerates lassa virus fusion and potently promotes fusion pore dilation upon forcing viral fusion with non-endosomal membrane. PLOS Pathog. 2022;18(8):e1010625. doi: 10.1371/journal.ppat.1010625
   PubMed Web of Science ®Google Scholar
• Weiss CD, Wang W, Lu Y, et al. Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A/H3N2 Outbreak among unvaccinated military recruits. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;71(12):3096–3102. doi: 10.1093/cid/ciz1198
   Web of Science ®Google Scholar
• Bi J, Wang H, Han Q, et al. A rabies virus-vectored vaccine expressing two copies of the marburg virus glycoprotein gene induced neutralizing antibodies against marburg virus in humanized mice. Emerg Microbes Infect. 2023;12(1):2149351. doi: 10.1080/22221751.2022.2149351
   PubMed Web of Science ®Google Scholar
• Sholukh AM, Fiore-Gartland A, Ford ES, et al. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. J Clin Microbiol. 2021;59(10):e00527–21. doi: 10.1128/JCM.00527-21
   PubMed Web of Science ®Google Scholar
• Condor Capcha JM; Lambert G; Dykxhoorn DM; Salerno AG; Hare JM; Whitt MA; Pahwa S; Jayaweera DT; Shehadeh LA. Generation of SARS-CoV-2 spike pseudotyped virus for viral entry and neutralization assays: a 1-week protocol. Front Cardiovasc Med. 2021;7:7. doi: 10.3389/fcvm.2020.618651
   Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065. doi: 10.1128/CVI.00131-10
   PubMed Web of Science ®Google Scholar
• Cantoni D; Wilkie C; Bentley EM; Mayora-Neto M; Wright E; Scott S; Ray S; Castillo-Olivares J; Heeney JL; Mattiuzzo G; Temperton NJ. Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Front Immunol. 2023;14:1184362. doi: 10.3389/fimmu.2023.1184362
   PubMed Web of Science ®Google Scholar
• Bentley EM; Mather ST; Temperton NJ. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination. Vaccine. 2015;33(26):2955–2962. doi: 10.1016/j.vaccine.2015.04.071
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5(10):705–719. doi: 10.4161/hv.5.10.9518
   PubMed Web of Science ®Google Scholar
• Draper E, Bissett SL, Howell-Jones R, et al. A randomized, observer-blinded immunogenicity trial of cervarix® and gardasil® human papillomavirus vaccines in 12-15 year old girls. PLoS One. 2013;8(5):e61825. doi: 10.1371/journal.pone.0061825
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection. Bio-Protoc. 2016;6(23):e2035. doi: 10.21769/BioProtoc.2035
   PubMedGoogle Scholar
• Pollet J, Chen W-H, Versteeg L, et al. SARS‑CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-Cell Immunity in Mice. Hum Vaccines Immunother. 2021;17(8):2356–2366. doi: https://doi.org/10.1080/21645515.2021.1901545
   PubMed Web of Science ®Google Scholar
• Kuzmina A, Khalaila Y, Voloshin O, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021;29(4):522–528.e2. doi: 10.1016/j.chom.2021.03.008
   PubMed Web of Science ®Google Scholar
• Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C. Developing pseudovirus-based neutralization assay against omicron-included SARS-CoV-2 variants. Viruses. 2022;14(6):1332. doi: 10.3390/v14061332
   PubMed Web of Science ®Google Scholar
• Crawford KHD, Eguia R, Dingens AS, et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12(5):513. doi: 10.3390/v12050513
   PubMed Web of Science ®Google Scholar
• Almahboub SA; Algaissi A; Alfaleh MA; ElAssouli M-Z; Hashem AM. Evaluation of neutralizing antibodies against highly pathogenic coronaviruses: a detailed protocol for a rapid evaluation of neutralizing antibodies using vesicular stomatitis virus pseudovirus-based assay. Front Microbiol. 2020;11:11. doi: 10.3389/fmicb.2020.02020
   Web of Science ®Google Scholar
• Zheng Y, Larragoite ET, Williams ESCP, et al. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. Virol J. 2021;18(1):1. doi: 10.1186/s12985-020-01472-1
   PubMed Web of Science ®Google Scholar
• Johnson MC, Lyddon TD, Suarez R, et al. Optimized pseudotyping conditions for the SARS-COV-2 spike glycoprotein. J Virol. 2020;94(21):e01062–20. doi: 10.1128/JVI.01062-20
   PubMed Web of Science ®Google Scholar
• Nova N. Cross-species transmission of coronaviruses in humans and domestic mammals, what are the ecological mechanisms driving transmission, spillover, and disease emergence? Front Public Health. 2021;9:717941. doi: 10.3389/fpubh.2021.717941
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei M, Wu Y, et al. Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Cell Rep. 2022;38(12):110558. doi: 10.1016/j.celrep.2022.110558
   PubMed Web of Science ®Google Scholar
• Wang H; Zhang L; Liang Z; Nie J; Wu J; Li Q; Ding R; Zhang Y; Chen G; Wang Y; Wang H; Huang W. Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in portugal. Arch Virol. 2022;167(2):459–470. doi: 10.1007/s00705-021-05327-0
   PubMed Web of Science ®Google Scholar
• Liu DX, Liang JQ, Fung TS. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Encycl virol. 2021:428–440. doi: 10.1016/B978-0-12-809633-8.21501-X
   Google Scholar
• Vlasova AN, Diaz A, Damtie D, et al. Novel canine coronavirus isolated from a hospitalized patient with pneumonia in East Malaysia. Clin Infect Dis. 2022;74(3):446–454. doi: 10.1093/cid/ciab456
   PubMed Web of Science ®Google Scholar
• Sánchez CA; Li H; Phelps KL; Zambrana-Torrelio C; Wang L-F; Zhou P; Shi Z-L; Olival KJ; Daszak P. A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia. Nat Commun. 2022;13(1):4380. doi: 10.1038/s41467-022-31860-w
   PubMed Web of Science ®Google Scholar
• Mkhize NN, Yssel AEJ, Kaldine H, et al. Neutralization profiles of HIV-1 viruses from the VRC01 antibody mediated prevention (AMP) trials. PLOS Pathog. 2023;19(6):e1011469. doi: 10.1371/journal.ppat.1011469
   PubMed Web of Science ®Google Scholar
• Al-Fattah Yahaya AA; Khalid K; Lim HX; Poh CL. Development of next generation vaccines against SARS-CoV-2 and variants of concern. Viruses. 2023;15(3):624. doi: 10.3390/v15030624
   PubMed Web of Science ®Google Scholar
• Kumari M; Su S-C; Liang K-H; Lin H-T; Lu Y-F; Chen K-C; Chen W-Y; Wu H-C. Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern. J Biomed Sci. 2023;30(1):46. doi: 10.1186/s12929-023-00936-0
   PubMed Web of Science ®Google Scholar
• Sehr P, Rubio I, Seitz H, et al. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One. 2013;8(10):e75677. doi: 10.1371/journal.pone.0075677
   PubMed Web of Science ®Google Scholar